Zymeworks (ZYME) EBT (2021 - 2026)

Zymeworks has reported EBT for 6 years, with the latest figure at -$46.4 million in Q1 2026.

• Quarterly EBT fell 109.36% year-over-year to -$46.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$104.0 million (up 2.99% YoY) and the FY2025 annual result came in at -$79.8 million, up 31.61% from the prior year.
• EBT declined to -$46.4 million in Q1 2026 per ZYME's latest filing, from -$41.5 million in the prior quarter.
• Over five years, EBT peaked at $320.4 million in Q4 2022 and troughed at -$72.7 million in Q1 2022.
• A 5-year average of -$13.3 million and a median of -$29.6 million in 2024 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2025: EBT soared 890.75% in 2022, then tumbled 133.15% in 2025.
• Over 5 years, EBT stood at $320.4 million in 2022, then plunged by 105.99% to -$19.2 million in 2023, then advanced by 7.36% to -$17.8 million in 2024, then sank by 133.15% to -$41.5 million in 2025, then dropped by 11.75% to -$46.4 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$46.4 million, -$41.5 million, and -$18.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.